“Telehealth really helped salvage some of the care that was deferred during the early part of the pandemic, and it’s really here to stay,” says Chad Ellimoottil, MD, MS.
In this video from the 2021 LUGPA annual meeting, Chad Ellimoottil, MD, MS, discusses the COVID-19 pandemic’s impact on telemedicine uptake among urologists as well as how he prepares differently for a telemedicine vs an in-person appointment. Ellimoottil is Assistant Professor of Urology and Director of the University of Michigan’s Telehealth Research Incubator.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.